Cervical cytology screening has been shown to reduce the incidence and mortality of squamous cell carcinoma of the cervix and increase the cure rate of cervical cancer. Screening protocol: 1. It is recommended that women start primary screening at the age of 21 years. 2.For those aged 21-29 years, cytology (cervical TCT) every 2-3 years, and feedback HPV testing is feasible if the TCT is ASC-US. 3.For those aged 30-65 years, the preferred option is cytology and high-risk HPV co-testing every 3-5 years; the other option is cytology alone, every 2-3 years. 4. If TCT is negative and high-risk HPV is positive at the time of co-testing: ① for those with typing, if 16 or 18 is negative, TCT and high-risk HPV will be repeated after 12 months; if 16 or 18 is positive, direct colposcopic biopsy; ② for those without typing, TCT and high-risk HPV will be repeated after 12 months. 5. If high-risk HPV is negative at the time of co-testing and TCT is ASC -US: follow-up routine screening by age, for example, for those aged 21-29, cytology every 2-3 years; for those aged 30-65, the priority program is cytology and high-risk HPV co-testing every 3-5 years; the other program is cytology alone, every 2-3 years. 6. Discontinue screening for women over 65 years of age with a history of negative results on routine screening and no history of CIN grade II or higher in the past 20 years. (History of negative results on routine screening is defined as 3 consecutive negative cytology results or 2 consecutive double negative tests for both cytology and high-risk HPV in the 10 years prior to discontinuation of screening, and the most recent screening within 5 years.) 7. Women who have undergone total hysterectomy and do not have a history of CIN grade II or higher should discontinue screening for vaginal cancer regardless of age and do not require an appropriate history of negative results on routine screening. 8. Screening for women with HPV vaccination: Screening protocols should not be changed based on HPV vaccination or not. 9. Screening protocols are developed for cervical cancer screening in the general population, and some frequently revised or other screening protocols are needed for some specific high-risk groups.